Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana Prior Auth & Notification Update | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana Dual Fully Integrated Illinois prior authorization and notification list

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and notification requirements for medications and certain services for Humana Dual Fully Integrated (HMO D-SNP) Illinois plans; applies to providers furnishing covered items or services to affected Humana members.

    Policy Summary
    PayerHumana
    PolicyHumana Dual Fully Integrated Illinois prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeAdministrative — no material coverage changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization via CoverMyMeds, phone (866-461-7273 TTY 711) or fax (888-447-3430) before providing listed medications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90-daygrace period for active courses of treatment
    3ways to initiate prior authorization
    up to 6max diagnosis codes per request
    866-461-7273prior auth phone
    888-447-3430prior auth fax
    HCPCS/CPTbilling codes provided

    Coverage criteria and medication list

    Coverage stance and criteria

    Covered when ALL of the following are met:

    Medications delivered in the provider's office, clinic, outpatient or home setting require prior authorization before being provided or administered.
    Services and items meet Medicare/CMS medical necessity and coverage guidelines.
    When applicable, step therapy requirements for Medicare Part B medications are followed (see Humana Part B Step Therapy PDL).
    Urgent or emergent services are excluded from prior authorization requirements.
    For new Humana members, active courses of treatment started prior to enrollment may continue without prior authorization for a 90-day transition period where applicable.
    Policy Summary
    PayerHumana
    PolicyHumana Dual Fully Integrated Illinois prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeAdministrative — no material coverage changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization via CoverMyMeds, phone (866-461-7273 TTY 711) or fax (888-447-3430) before providing listed medications.
    SourceLink
    On This Page
    Coverage criteria and medication listBilling and coding referencesPrior authorization process and provider instructionsNotation legend and definitions
    Failure to obtain required prior authorization may result in retrospective medical necessity review and potential financial penalties or reduced benefits.

    Coverage criteria and procedural requirements (excerpt)

    Requirements and procedural expectations (excerpt):

    Prior authorization is required for drugs listed on the prior authorization and notification list; providers must submit requests via the specified submission methods or fax forms noted in the list.
    All shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims when applicable (‡ flag).
    Some products are subject to step therapy through a Humana-preferred drug as part of preauthorization (flagged with **); follow the Part B Step Therapy PDL and coverage policies.
    Certain preauthorization requests for transplant-related therapies will be reviewed by the Humana National Transplant Network; follow the provided fax/phone/email submission channels (†† flag).

    Prior authorization and billing criteria (excerpt)

    Prior authorization and billing criteria (excerpt):

    Listed medications require prior authorization or provider notification per the Humana prior authorization list; follow the Humana instructions for submitting requests.
    For shared HCPCS and NOC billing codes, the corresponding NDC must be included on claims (‡).
    Step therapy requirements may apply for selected medications and are indicated by the ** flag; providers must satisfy step requirements where applicable as part of authorization.
    Transplant-related prior authorization requests are subject to review by the Humana National Transplant Network and must follow the specified submission methods (fax/phone/email).

    Medication prior authorization entries (sample)

    Selected medication entries from the prior authorization and notification list (sample):

    Vabysmo (faricimab-svoa) — Billing code: J3358 — prior authorization required; step therapy flag (**) may apply.
    Velcade (bortezomib) — Billing code: J9041 — prior authorization required; marked with ‡ indicating NDC must be billed with shared/NOC HCPCS as applicable.
    Blood‑clotting factor products (examples): Advate — J7192; Adynovate — J7207; Hemlibra — J7170 — these products are listed on the PA/notification list and require prior authorization.

    Billing and coding references

    Representative HCPCS/J-codesHCPCS
    J9299Not otherwise classified antineoplastic/chemotherapy drug
    J9305Pemetrexed-based product
    J9314Pemetrexed (Teva)
    J9294Pemetrexed disodium (Hospira)
    J9323Pemetrexed ditromethamine
    J9304Pemfexy (pemetrexed injection)
    J9324Pemrydi RTU (pemetrexed)
    Billing Instructionsmixed
    Billing ruleAll shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    Max diagnosis codesUp to a maximum of 6 diagnosis codes per authorization request.
    Step therapySome drugs require step therapy through a Humana-preferred drug as part of preauthorization (see drug list for **).
    Transplant reviewPreauthorization requests for transplant-related drugs will be reviewed by the Humana National Transplant Network (fax 502-508-9300; phone 866-421-5663; transplant@humana.com).
    Examples of drug billing codesHCPCS
    J9042Adcetris (brentuximab vedotin)
    J3262Actemra IV (tocilizumab)
    J9264Abraxane (paclitaxel-nab)
    J1426Amondys-45 (casimersen)
    Q2055Abecma (idecabtagene vicleucel) — Q-code
    Q2054Breyanzi (lisocabtagene maraleucel) — Q-code
    A9607Pluvicto (lutetium Lu 177 vipivotide tetraxetan) — A-code
    Selected J-/Q-/A- codes in excerptHCPCS
    J1745Infliximab
    J1439Injectafer (ferric carboxymaltose)
    J9183Gemcitabine
    J9319Istodax (romidepsin)
    J9207Ixempra (ixabepilone)
    J9281Jelmyto (mitomycin)
    J9176Empliciti (elotuzumab)
    Selected product HCPCS/J codes from excerptHCPCS
    J9306Perjeta (pertuzumab)
    J9316Phesgo (pertuzumab/trastuzumab/hyaluronidase)
    J9309Polivy (polatuzumab vedotin)
    J1203Pombiliti (cipaglucosidase alfa)
    J9295Portrazza (necitumumab)
    J9204Poteligeo (mogamulizumab-kpkc)
    Sample medication billing codesHCPCS
    J9035(example placeholder)
    J3358(example placeholder)
    J2777Vabysmo (faricimab-svoa)
    J9357Valstar (valrubicin)
    J9303Vectibix (panitumumab)
    J9041Velcade (bortezomib)
    J1412Roctavian (valoctocogene roxaparvovec)

    Prior authorization process and provider instructions

    Prior Authorization

    Exceptions - urgent/emergent services

    Urgent or emergency services do not require prior authorization or referrals. If a member presents with an urgent or emergent condition, providers should deliver necessary care immediately and may notify Humana after the service is rendered. Retrospective review may be performed to confirm medical necessity, but lack of prior authorization for urgent/emergent care will not be used as a basis to deny coverage when the service met emergency care criteria.

    • Do not delay clinically necessary emergency treatment to obtain prior authorization.
    • Providers may notify Humana after the emergent/urgent service; follow plan-specific notification processes when feasible.
    • Services provided for urgent or emergent conditions are subject to retrospective medical necessity review but are not denied solely for lack of prior authorization.

    Notation legend and definitions

    Prior authorization (definition)
    DefinitionPrior authorization is the process through which the healthcare provider must obtain advance approval from the plan to determine whether an item or service will be covered.
    ScopeApplies to medications delivered in the provider's office, clinic, outpatient or home settings and to services that must meet Medicare/CMS medical necessity guidelines.
    ExceptionInvestigational and experimental procedures and devices usually are not covered; consult Evidence of Coverage or Humana for confirmation.
    Document notation legend
    * (asterisk)New preauthorization requirement
    † (dagger)New-to-market drug addition
    ‡ (double dagger)All shared HCPCS and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims
    HCPCS shared/NOC NDC billing requirement
    Requirement summaryAll shared HCPCS codes and not otherwise classified (NOC) codes must include a corresponding National Drug Code (NDC) on claims
    Affected codesShared HCPCS and NOC codes (e.g., C9399, J3490) are noted in the drug list as requiring NDCs
    Submission impactClaims for affected products without the corresponding NDC may not meet billing requirements—follow listed notation when submitting authorization and claims
    Step therapy flag
    Flag meaning** indicates step therapy is required through a Humana-preferred drug as part of preauthorization
    Where usedStep therapy flag appears next to specific Part B medications in the prior authorization list
    Action for providersConsult Humana's Part B Step Therapy Preferred Drug List and coverage criteria when submitting authorization
    Notation legend
    * (new preauthorization)Indicates a new preauthorization requirement has been added for the listed product
    † (new-to-market)Denotes a new-to-market drug addition to the list
    †† (transplant review)Indicates requests will be reviewed by the Humana National Transplant Network (submission contact details provided)
    Step therapy required through a Humana-preferred drug
    Step therapy requirementStep therapy may be required through a Humana-preferred drug as part of preauthorization (flagged with **)
    Relation to preauthorizationStep therapy is enforced during the preauthorization decision process for flagged products
    Reference materialsSee Humana's Medicare Part B Step Therapy Preferred Drug List and coverage policies for details
    NDC requirement for shared HCPCS and NOC codes
    Billing ruleAll shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims
    ExamplesC9399 and J3490 are listed in the document as examples of codes that require an NDC when billed
    Referenced in list entriesEntries in the prior authorization list include the ‡ notation to signal this billing requirement
    Humana National Transplant Network review
    Review bodyPreauthorization requests for transplant-related items will be reviewed by the Humana National Transplant Network
    Submission faxFax transplant requests to 502-508-9300
    Submission phone/emailPhone 866-421-5663 (Mon–Fri 7 a.m.–7 p.m. Central); email transplant@humana.com
    New preauthorization requirement
    New preauthorization marking* denotes a new preauthorization requirement for the listed product
    Where it appearsMarked next to individual drug entries throughout the prior authorization list
    Provider actionFollow instructions on the list and submit the required fax forms or electronic requests for newly added preauthorization requirements
    New-to-market drug addition
    New-to-market marking† denotes a new-to-market drug addition to the prior authorization list
    ImplicationNew-to-market drugs are added to the list and may carry special submission or review notes
    Provider guidanceCheck the drug entry for additional flags (e.g., ‡, **) and follow submission instructions
    ‡ (HCPCS/NOC NDC billing requirement)
    Symbol meaning‡ indicates shared HCPCS and NOC codes require a corresponding NDC on all claims
    Where usedAppears beside products such as Prevymis (C9399, J3490) and other entries requiring NDC billing
    Billing implicationWhen ‡ is present, include the NDC on all claims and in authorization/notification submissions as applicable
    ** (step therapy requirement)
    Symbol meaning** indicates step therapy is required through a Humana-preferred drug as part of preauthorization
    Examples in listMultiple injectable and specialty products in the list are flagged with ** to denote step therapy
    Provider actionDocument prior trials of preferred drugs when submitting authorization for **-flagged products
    †† (transplant review)
    Symbol meaning†† indicates preauthorization requests will be reviewed by the Humana National Transplant Network
    Submission channelsFax 502-508-9300; phone 866-421-5663; email transplant@humana.com
    HoursMonday–Friday, 7 a.m.–7 p.m. Central for transplant review phone support